Selandia Baru - Inggris - Ministry for Primary Industries

max(rudong) chemicals co., ltd. - prohexadione-calcium - prohexadione-calcium 100 g/kg - plant growth regulator

Uni Eropa - Inggris - EMA (European Medicines Agency)

linde healthcare ab - nitric oxide - hypertension, pulmonary; respiratory insufficiency - other respiratory system products - inomax, in conjunction with ventilatory support and other appropriate active substances, is indicated:for the treatment of newborn infants ≥34 weeks gestation with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension, in order to improve oxygenation and to reduce the need for extracorporeal membrane oxygenation;as part of the treatment of peri- and post-operative pulmonary hypertension in adults and newborn infants, infants and toddlers, children and adolescents, ages 0-17 years in conjunction to heart surgery, in order to selectively decrease pulmonary arterial pressure and improve right ventricular function and oxygenation.

Amerika Serikat - Inggris - NLM (National Library of Medicine)

the medicines company - bivalirudin (unii: tn9bex005g) (bivalirudin - unii:tn9bex005g) - bivalirudin 250 mg - angiomax is indicated for use as an anticoagulant for use in patients undergoing percutaneous coronary intervention (pci) including patients with heparin-induced thrombocytopenia and heparin-induced thrombocytopenia and thrombosis syndrome. angiomax is contraindicated in patients with: risk summary there are no data available on use of angiomax in pregnant women to inform a drug-associated risk of adverse developmental outcomes. reproduction studies in rats and rabbits administered subcutaneously doses up to 1.6 times and 3.2 times the maximum recommended human dose (mrhd) of 15 mg/kg/day based on body surface area (bsa) during organogenesis, respectively, revealed no evidence of fetal harm. all pregnancies have a background risk of birth defect, loss, or other adverse outcomes. the estimated background risk of major birth defects and miscarriage for the indicated population is unknown. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recogniz

Amerika Serikat - Inggris - NLM (National Library of Medicine)

ino therapeutics llc - nitric oxide (unii: 31c4ky9esh) (nitric oxide - unii:31c4ky9esh) - nitric oxide 0.98 mg in 1 l - inomax® is indicated to improve oxygenation and reduce the need for extracorporeal membrane oxygenation in term and near-term (>34 weeks gestation) neonates with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension in conjunction with ventilatory support and other appropriate agents. inomax is contraindicated in neonates dependent on right-to-left shunting of blood. the safety and efficacy of nitric oxide for inhalation has been demonstrated in term and near-term neonates with hypoxic respiratory failure associated with evidence of pulmonary hypertension [see clinical studies (14.1)]. additional studies conducted in premature neonates for the prevention of bronchopulmonary dysplasia have not demonstrated substantial evidence of efficacy [see clinical studies (14.3)]. no information about its effectiveness in other age populations is available. nitric oxide is not indicated for use in the adult population.

Amerika Serikat - Inggris - NLM (National Library of Medicine)

sandoz inc - bivalirudin (unii: tn9bex005g) (bivalirudin - unii:tn9bex005g) - angiomax is indicated for use as an anticoagulant for use in patients undergoing percutaneous coronary intervention (pci) including patients with heparin-induced thrombocytopenia and heparin-induced thrombocytopenia and thrombosis syndrome. angiomax is contraindicated in patients with: risk summary there are no data available on use of angiomax in pregnant women to inform a drug-associated risk of adverse developmental outcomes. reproduction studies in rats and rabbits administered subcutaneously doses up to 1.6 times and 3.2 times the maximum recommended human dose (mrhd) of 15 mg/kg/day based on body surface area (bsa) during organogenesis, respectively, revealed no evidence of fetal harm. all pregnancies have a background risk of birth defect, loss, or other adverse outcomes. the estimated background risk of major birth defects and miscarriage for the indicated population is unknown. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recogniz

Australia - Inggris - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - topiramate, quantity: 50 mg - capsule, hard - excipient ingredients: povidone; cellulose acetate; maize starch; sucrose; titanium dioxide; sorbitan monolaurate; potable water; gelatin; sodium lauryl sulfate; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; iron oxide black; shellac glaze-45% (20% esterified) in ethanol - epilepsy topamax is indicated in adults and children, 2 years and over: as monotherapy in patients with newly diagnosed epilepsy; for conversion to monotherapy in patients with epilepsy; as add-on therapy in partial onset seizures (with or without secondary generalised seizures), primary generalised tonic-clonic seizures or drop attacks associated with lennox-gastaut syndrome; migraine topamax is indicated for the prophylaxis of migraine headache in adults. the usefulness of topamax in the acute treatment of migraine headache has not been studied.

Australia - Inggris - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - topiramate, quantity: 25 mg - capsule, hard - excipient ingredients: cellulose acetate; povidone; titanium dioxide; sorbitan monolaurate; potable water; gelatin; sodium lauryl sulfate; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; iron oxide black; shellac glaze-45% (20% esterified) in ethanol; maize starch; sucrose - epilepsy topamax is indicated in adults and children, 2 years and over: as monotherapy in patients with newly diagnosed epilepsy; for conversion to monotherapy in patients with epilepsy; as add-on therapy in partial onset seizures (with or without secondary generalised seizures), primary generalised tonic-clonic seizures or drop attacks associated with lennox-gastaut syndrome; migraine topamax is indicated for the prophylaxis of migraine headache in adults. the usefulness of topamax in the acute treatment of migraine headache has not been studied.

Australia - Inggris - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - topiramate, quantity: 15 mg - capsule, hard - excipient ingredients: cellulose acetate; povidone; titanium dioxide; sorbitan monolaurate; potable water; gelatin; sodium lauryl sulfate; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; iron oxide black; shellac glaze-45% (20% esterified) in ethanol; maize starch; sucrose - epilepsy topamax is indicated in adults and children, 2 years and over: as monotherapy in patients with newly diagnosed epilepsy; for conversion to monotherapy in patients with epilepsy; as add-on therapy in partial onset seizures (with or without secondary generalised seizures), primary generalised tonic-clonic seizures or drop attacks associated with lennox-gastaut syndrome; migraine topamax is indicated for the prophylaxis of migraine headache in adults. the usefulness of topamax in the acute treatment of migraine headache has not been studied.

Australia - Inggris - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - topiramate, quantity: 200 mg - tablet, film coated - excipient ingredients: magnesium stearate; lactose monohydrate; pregelatinised maize starch; carnauba wax; microcrystalline cellulose; sodium starch glycollate; titanium dioxide; hypromellose; polysorbate 80; iron oxide red; macrogol 400 - epilepsy topamax is indicated in adults and children, 2 years and over: as monotherapy in patients with newly diagnosed epilepsy; for conversion to monotherapy in patients with epilepsy; as add-on therapy in partial onset seizures (with or without secondary generalised seizures), primary generalised tonic-clonic seizures or drop attacks associated with lennox-gastaut syndrome; migraine topamax is indicated for the prophylaxis of migraine headache in adults. the usefulness of topamax in the acute treatment of migraine headache has not been studied.

Australia - Inggris - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - topiramate, quantity: 100 mg - tablet, film coated - excipient ingredients: lactose monohydrate; pregelatinised maize starch; carnauba wax; magnesium stearate; sodium starch glycollate; microcrystalline cellulose; titanium dioxide; hypromellose; polysorbate 80; iron oxide yellow; macrogol 400 - epilepsy topamax is indicated in adults and children, 2 years and over: as monotherapy in patients with newly diagnosed epilepsy; for conversion to monotherapy in patients with epilepsy; as add-on therapy in partial onset seizures (with or without secondary generalised seizures), primary generalised tonic-clonic seizures or drop attacks associated with lennox-gastaut syndrome; migraine topamax is indicated for the prophylaxis of migraine headache in adults. the usefulness of topamax in the acute treatment of migraine headache has not been studied.